← All trials
NCT06673459
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2024
- Primary completion
- Nov 30, 2029
- Completion date
- Nov 30, 2029
- First posted
- Nov 5, 2024
- Last posted
- Nov 5, 2024
- Enrollment
- 430
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Soochow UniversityLead sponsor
- Zhejiang UniversityCollaborator
- Anhui Medical UniversityCollaborator
- Soochow UniversitySponsor investigator
- Huazhong University of Science and TechnologyCollaborator
- Fujian Medical UniversityCollaborator
- Southern Medical UniversityCollaborator
- Soochow UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.